Hanmi Pharmaceutical introduced on Nov. 5 that it has signed an unique provide and license settlement with Vietnamese pharmaceutical firm VietPhap to export hypertension mixture medicine to the native market.
The corporate mentioned that the contract ceremony was held with Park Jae-hyun, CEO of Hanmi Pharmaceutical, and Nguyen Chi Trung, CEO of VietPhap, in attendance at CPHI Worldwide 2025 held in Frankfurt, Germany from Oct. 28-30. VietPhap was established in Hanoi, Vietnam in 2002 and is evaluated as one of many main pharmaceutical firms domestically.
Below the settlement, Hanmi Pharmaceutical will provide completed hypertension mixture drug merchandise to VietPhap, whereas VietPhap might be chargeable for licensing, distribution, and gross sales inside the Vietnamese area. Vietnam’s hypertension sufferers are estimated at roughly 15 million, and the associated therapy market can also be repeatedly rising at an annual scale of $40 million.
By way of this cooperation, each firms plan to develop entry to hypertension therapies within the Vietnamese area and give attention to resolving unmet medical wants of native sufferers and enhancing the therapy surroundings. Moreover, beginning with this contract, they agreed to carefully cooperate for the profitable entry of main new medicine developed by Hanmi Pharmaceutical into the Vietnamese market.
Park mentioned, “By way of this cooperation with VietPhap, we’ve got established a basis for Hanmi Pharmaceutical’s consultant hypertension mixture drug to determine a secure place within the Vietnamese market.” CEO Nguyen additionally mentioned, “Along with hypertension therapies with Hanmi Pharmaceutical, we want to proceed cooperation by introducing merchandise in numerous unmet medical want areas.”
